Archives
-
Chronic Stress, Mitochondria, and Depression-Like Behavior
2026-10-07
A 2025 Psychoneuroendocrinology study links chronic unpredictable mild stress in rats with mitochondrial dysfunction and neuroinflammatory changes in the hippocampus and prefrontal cortex. Its MnTBAP intervention provides causal-supporting evidence that mitochondrial redox disruption contributes to stress-associated depression-like behavior, while remaining limited to a preclinical animal model.
-
Tankyrase Inhibition and Hippo Signaling in HCC
2026-10-07
Jia et al. reported that the tankyrase inhibitors XAV-939 and G007-LK restrained growth across human hepatocellular carcinoma models and reduced YAP pathway activity. The study’s central contribution is its evidence that tankyrase inhibition can influence the Hippo cascade through increased AMOTL1 and AMOTL2, while its cell-based design supports mechanistic follow-up rather than clinical conclusions.
-
ATP Luminescence in Glioblastoma Cell Studies
2026-10-06
A source-grounded overview of ATP-based luminescence for cell viability measurement, with emphasis on interpreting antiproliferative findings in glioblastoma models and distinguishing supplier claims from independently reported evidence.
-
Vasopressin Analogues: Evidence, Design, and Applications
2026-10-06
Glavaš and colleagues present an integrative review of how vasopressin structure, receptor signaling, peptide stability, and clinical use shape the design of vasopressin analogues. Its main practical implication is that compounds such as lypressin, desmopressin, and terlipressin should be evaluated as pharmacologically differentiated peptides rather than interchangeable vasopressin substitutes.
-
CAMLs in Blood: Phenotype and Clinical Utility
2026-10-05
The 2025 Cancer Letters study evaluates circulating phagocytic polyploid giant cancer macrophages, or CAMLs, across 293 patients with six solid tumor types. Its prospective, multi-institutional findings associate CAMLs with progression and disease spread while describing cellular traits consistent with a possible role in metastatic niche biology, although the study does not establish causality.
-
Shh–Fgf Control of Penile Development
2026-10-05
A 2025 Cells study compares penile development in guinea pigs and mice to explain why the two species form the urethral groove and prepuce differently. Its integrated expression and tissue-perturbation evidence implicates differential Shh and Fgf10/Fgfr2 activity, while also highlighting the limits of extending mouse findings to human development.
-
Fast HepaRG Differentiation for HBV and HDV Models
2026-10-04
Lucifora and colleagues report a chemical strategy that shortens HepaRG differentiation while preserving efficient hepatitis D virus infection. The study also reveals an important distinction: accelerated cells support HDV replication well, but show weaker HBV cccDNA establishment and downstream replication markers than conventionally differentiated cells.
-
Iptacopan (LNP023): Evidence in PNH
2026-10-03
Iptacopan is an oral, selective factor B inhibitor designed to suppress alternative-pathway amplification. A small, open-label phase 2 study in paroxysmal nocturnal hemoglobinuria reported rapid improvements in hemolysis, hemoglobin, and transfusion status. The findings support biological plausibility, but limited sample size, lack of a comparator, short follow-up, and interim analysis constrain conclusions about comparative efficacy, long-term safety, and use beyond PNH.
-
Iptacopan (LNP023) Complement Research Workflows
2026-10-02
Iptacopan (LNP023) enables selective interrogation of alternative-pathway amplification in serum, erythrocyte, and disease-model workflows. This practical guide connects factor B inhibition with assay design, controls, troubleshooting, and translational interpretation.
-
Primidone: A Mechanism-First Research Guide
2026-10-01
Primidone (Mysoline) is more than a conventional antiepileptic: its concentration-dependent effects on TRPM3, RIPK1, and hPON1 require mechanism-specific interpretation. This guide connects structural biology with practical assay design across neurodevelopmental, neurodegenerative, and adenomyosis research.
-
Pseudo-UTP for High-Performance mRNA Synthesis
2026-10-01
Pseudo-UTP enables controlled pseudouridine incorporation during in vitro transcription, helping researchers optimize RNA persistence, translation, and innate immune compatibility. This guide connects reagent selection with practical workflows for mRNA vaccine development, gene therapy RNA modification, and mRNA/LNP cancer-immunology studies.
-
Gut Dysbiosis, STAT3, and Docetaxel Resistance
2026-09-30
Zhong et al. identify a microbiome–tumor communication route in which antibiotic-associated dysbiosis increases intestinal permeability and intratumoral lipopolysaccharide, activating the NF-κB–IL6–STAT3 axis in prostate cancer. The study combines mouse models, fecal microbiota transplantation, 16S rRNA profiling, mechanistic assays, and patient data to connect microbial composition with tumor progression and docetaxel resistance.
-
EGFP mRNA Workflows for RNA Delivery
2026-09-30
Use EGFP mRNA as a practical fluorescent benchmark for comparing RNA delivery, cell entry, and protein-expression workflows. This guide connects a capped, modified reporter transcript with the emerging potato virus X nucleoprotein platform while separating evidence-backed findings from recommended assay starting points.
-
Anti-DLL3 Antibody: SCLC Research Workflows
2026-09-29
Build a DLL3 research workflow that moves from protein detection and cell-surface profiling to functional and preclinical studies. The Dragonfly patent anti-DLL3 format adds an unconjugated, flexible reagent for evaluating target biology alongside emerging transient DLL3-directed CAR-T strategies.
-
Lypressin Acetate: From Receptor Biology to Translation
2026-09-29
A translational framework for using Lypressin acetate to connect vasopressin receptor pharmacology, endocrine research, vasopressor assays, and carefully bounded antiviral hypotheses.